Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

METHIMAZOLE

All products: general benefit

Jamp Methimazole · DIN 02490625 · 5mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Methimazole · DIN 02490625 Manufacturer: Jamp Pharma Corporation; listing date 2020-10-30 Health Canada: Marketed since 2020-08-21 · brand JAMP METHIMAZOLE · ATC H03BB02 THIAMAZOLE · form Tablet · route Oral · ingredients METHIMAZOLE 5 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Methimazole: Formulary list price $0.1531/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1531 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98069 · Verify on the e-Formulary ↗ (DIN 02490625)

Source record
DIN 02490625: Jamp Methimazole Raw flags: sec3=Y Item: 683800001; group id 808; item number 1985; lccId None; manufacturer id JPC Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.1531; ministry $0.1531 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02490625 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98069
Interchangeable products
Mar-Methimazole · DIN 02480107 · $0.1531 Tapazole · DIN 00015741 · $0.1531
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:38 Anti-Thyroids) and how they are covered
No products matched this class search: “68:38”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS MAR-METHIMAZOLE is indicated in adults for: • The medical treatment of hyperthyroidism. Long-term therapy may lead to remission of the disease. • Amelioration of hyperthyroidism in preparation for subtotal thyroidectomy or radioactive iodine therapy. • Use when thyroidectomy is contraindicated or not advisable. 1.1. Pediatrics Pediatrics (<18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics (≥ 65 years): Clinical studies did not include sufficient numbers of subjects aged 65 years or older to determine the safety and efficacy of methimazole in this geriatric population (see 4.2 Recommended Dose and Dosage Adjustment and 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00072961.PDF PM date: October 10, 2023 Source product: MAR-METHIMAZOLE; DIN 02480107; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.